A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozoleSpringerPlus - Tập 5 - Trang 1-12 - 2016
Katharina Gunzer, Florence Joly, Jean-Marc Ferrero, Joseph Gligorov, Helene de Mont-Serrat, Martina Uttenreuther-Fischer, Katy Pelling, Sven Wind, Guilhem Bousquet, Jean-Louis Misset